Welcome to our dedicated page for Purple Biotech SEC filings (Ticker: PPBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Purple Biotech Ltd. (PPBT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Purple Biotech files its annual report on Form 20-F and furnishes current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with registration statements on Forms F-1, F-3 and S-8, outline the company’s clinical-stage oncology strategy, financing activities, and corporate actions.
Through its Form 6-K reports, Purple Biotech furnishes press releases and corporate presentations that describe its oncology pipeline, including the CAPTN-3 tri-specific antibody platform, the CEACAM1-blocking antibody CM24, and the dual IRS1/2 and STAT3 inhibitor NT219. Filings reference milestones such as manufacturing achievements for IM1240, preclinical and clinical data updates, European patent developments for NT219 combinations, and collaborations with academic institutions. They also include financial results, at-the-market offering agreements, and details of public offerings of American Depositary Shares and warrants.
Investors use Purple Biotech’s SEC filings to review quarterly and interim financial information furnished on Form 6-K, as well as capital markets transactions such as shelf registrations on Form F-3 and follow-on offerings. The filings also document corporate governance events, including notices and results of shareholder meetings, and incorporate certain reports by reference into existing registration statements.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify information on pipeline progress, financing terms, and listing compliance matters. Users can follow new 6-K submissions in near real time as they are posted to EDGAR, and then drill into specific exhibits such as press releases or corporate presentations for more detail.
For those researching PPBT, this page serves as a central location to review Purple Biotech’s official SEC communications related to its clinical programs, financial position, and securities offerings, all organized chronologically with concise AI-generated overviews.
Purple Biotech Ltd. reported new preclinical results for IM1240, the lead tri-specific antibody from its CAPTN-3 platform. In lab studies run at the Icahn School of Medicine at Mount Sinai, all seven tested patient-derived, treatment-resistant tumor samples responded to IM1240.
The data highlight the role of IM1240’s NKG2A arm: when this binding domain was mutated, apoptotic activity was lost across all samples, underscoring its contribution to anti-tumor effects. In a non-small cell lung cancer biopsy, IM1240 also induced mature tertiary lymphoid structures and increased CD8 T cells and NK cells while reducing Tregs and tumor cells.
The company describes CAPTN-3 as a platform of masked tri-specific antibodies designed to activate T cells and NK cells selectively in the tumor microenvironment. IM1240 and a second candidate, IM1305, remain in preclinical development, while other assets CM24 and NT219 are at clinical stage pending further partnering or investment.
Purple Biotech Ltd. reported that it has established a Scientific Advisory Board (SAB) to guide development of its CAPTN-3 tri-specific antibody immunotherapy platform. The SAB includes experts in T-cell engagers, NK and T cell biology, tumor immunology and clinical oncology, including leaders involved in foundational approved therapies.
CAPTN-3 is a platform of masked tri-specific antibodies designed to target tumor-associated antigens while engaging both T cells and NK cells, using proprietary capping technology to confine immune activation to the tumor microenvironment. Lead candidate IM1240 is advancing toward the clinic, while IM1305 remains in preclinical development.
Purple Biotech also highlights additional pipeline assets: CM24, a CEACAM1-blocking antibody that showed improved outcomes across all efficacy endpoints in a Phase 2 pancreatic ductal adenocarcinoma study, and NT219, a dual IRS1/2 and STAT3 inhibitor in a Phase 2 study for head and neck cancer.
PURPLE BIOTECH LTD. director Simcha Rock filed an initial ownership statement showing substantial equity-based compensation. He directly holds 3,207,690 Ordinary Shares, including 2,454,167 unvested restricted stock units that settle in shares. He also holds stock options to buy 300,000 shares at $0.059375 per share and 2,650,000 shares at $0.00309375 per share, with vesting schedules running through 2028 and expirations in 2028 and 2030. Each American Depositary Share currently represents 2,000 Ordinary Shares.
PURPLE BIOTECH LTD. director Suzana Zilberberg filed an initial ownership report showing her equity stake in the company. She directly holds 3,062,500 Ordinary Shares as of the reported date, including 2,454,167 unvested restricted stock units that will settle in Ordinary Shares.
She also holds stock options to purchase 112,500 Ordinary Shares at $0.126875 per share expiring on December 29, 2026, options for 300,000 Ordinary Shares at $0.059375 per share expiring on April 24, 2028, and options for 2,650,000 Ordinary Shares at $0.00309375 per share expiring on October 21, 2030, with portions of these options vesting over time.
PURPLE BIOTECH LTD. director Agmon Ido filed an initial ownership report showing substantial equity exposure. He beneficially owns 3,093,860 Ordinary Shares, including 2,454,167 unvested RSUs that settle in Ordinary Shares, and holds stock options over an additional 2,950,000 Ordinary Shares at low exercise prices.
PURPLE BIOTECH LTD. Chief Executive Officer Gil Efron reported his initial ownership, showing direct holdings of 15,750,000 Ordinary Shares. This includes 12,375,000 unvested restricted stock units that vest over time and are settled in Ordinary Shares, which may be represented by American Depositary Shares, each currently equal to 2,000 Ordinary Shares.
He also holds stock options to purchase 1,500,000 Ordinary Shares at $0.095054688 per share expiring on May 23, 2027; 3,750,000 Ordinary Shares at $0.0765625 per share expiring on July 11, 2027; and 13,500,000 Ordinary Shares at $0.00309375 per share expiring on October 21, 2030, with 1,125,000 already vested and the remaining 12,375,000 vesting in equal quarterly installments until October 21, 2028.
PURPLE BIOTECH LTD. Chief Financial Officer Shai S. Lankry has updated his reported equity holdings. The filing shows stock options to purchase 3,000,000 ordinary shares under one grant and 3,550,000 ordinary shares under another, all under the company’s 2016 Equity-Based Incentive Plan.
The options for 3,000,000 ordinary shares carry an exercise price of $0.01359375 per share and expire on April 29, 2030. The options for 3,550,000 ordinary shares have an exercise price of $0.00309375 per share and expire on October 21, 2030, with 295,833 shares already vested.
The holdings also include 3,254,167 unvested restricted stock units, each representing one ordinary share subject to time-based vesting and settled in ordinary shares. The ordinary shares may be represented by American Depositary Shares, with each ADS currently representing 2,000 ordinary shares.
PURPLE BIOTECH LTD. executive Michael Schickler filed an initial ownership report showing 9,254,472 Ordinary Shares, including 6,958,334 unvested restricted stock units that vest over time and settle in Ordinary Shares. He also holds several stock options over Ordinary Shares with exercise prices between $0.10828125 and $0.00309375 per share, expiring between April 2027 and October 2030, some already vested and others vesting in quarterly installments.
PURPLE BIOTECH LTD. director Shai S. Lankry filed an initial ownership report showing a sizable equity position. He holds 3,550,000 Ordinary Shares, including 3,254,167 unvested restricted stock units that settle in shares or ADSs. He also holds stock options to purchase 3,000,000 Ordinary Shares at an exercise price of $0.01359375 per share and options to purchase 3,550,000 Ordinary Shares at $0.00309375 per share, both vesting over several years and expiring in 2030.
Purple Biotech Ltd. filed a Form 6-K to furnish a press release announcing an AI-driven collaboration with Converge Bio to advance its next-generation tri-specific antibody platform. The partnership uses Converge Bio’s generative AI to design and optimize oncology-focused antibodies, aiming to speed discovery and improve molecule quality.
Purple Biotech plans to apply these AI insights to its CAPTN-3 platform of masked tri-specific antibodies that engage both T cells and NK cells, with lead candidates IM1240 and IM1305 in preclinical development. The company also highlights additional clinical-stage assets CM24 and NT219, whose further progress depends on partnering or investment.